Martina Brueckmann

Nov 4, 2024 | onlinelibrary.wiley.com | Sean Wharton |Mikhail Kosiborod |Elke Platz |Martina Brueckmann

What is already known? Antiobesity medications (AOMs) in conjunction with lifestyle changes are recommended for the treatment of obesity, but only a few AOMs are available to combat this highly prevalent and heterogenous disease. Survodutide is a dual glucagon and glucagon-like peptide-1 (GLP-1) receptor agonist under investigation for the treatment of obesity in people with BMI ≥ 30 kg/m2 or ≥27 kg/m2 with at least one obesity-related complication. What do these studies add?

Jun 9, 2024 | bpspubs.onlinelibrary.wiley.com | Juliane Rascher |Dan Cotton |Sebastian Haertter |Martina Brueckmann

What is already known about this subject Empagliflozin is approved for use in adults with T2D at a dose of 10 mg once daily with potential increase to 25 mg, HF independent of left ventricular ejection fraction, and chronic kidney disease at a dose of 10 mg once daily. Empagliflozin systemic exposure is similar between patients with T2D and healthy subjects at equivalent dose levels.